Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Estate Planning with Apple’s Legacy Contact

Client Alert

What happens to your Apple ID account when you die? Apple has created a feature among its products which allows you to choose one or more people to have access to your Apple ID account following your death. Apple refers to the online tool as a “Legacy Contact.” An Apple user may designate anyone to be their Legacy Contact, including those who do not own an Apple device or have an Apple ID. You can send the legacy contact a message that includes the access key, or you can print off a copy and keep it with your estate documents. At any time before your death, you may remove someone from being a Legacy Contact. The person you have removed will not receive a notification that they have been removed. However, their access key will no longer work.

If you are named as someone’s Legacy Contact and the account holder has passed, you can access their data by submitting a request to Apple with the access key that you received and the account holder’s death certificate. Once this information has been verified and access has been approved, the Legacy Contact will receive a special Apple ID to access the account data. The data a Legacy Contact may access includes photos, notes, mail, contacts, calendars, reminders, messages, call history, health data, Safari bookmarks, voice memos, and files stored. The Legacy Contact’s access only lasts for three years, and the account will be deleted permanently following the three-year period.

Apple’s new feature has a significant impact on estate planning. Under Ohio law, online tools such as Apple’s Legacy Contact supersede contrary directions in a person’s will, trust, power of attorney, or other record. This means that if you do not name the same person to be your Legacy Contact as you name in your will or trust, your Legacy Contact may act contrary to what your will or trust states. Therefore, it is important to consult with an experienced estate planning attorney when determining how to handle digital assets. Those who do not have a plan for their digital assets may be susceptible to identity theft, losses to the estate, exposure of secrets, and loss of sentimental data.

If you have any questions regarding Apple’s Legacy Contact or planning for your digital assets, please contact Cassandra Manna at clmanna@bmdllc.com or (216) 658-2206.


USCIS Policy Change Impacting Work Authorization: Advisory for Employers and Human Resources

USCIS has issued a policy memorandum pausing immigration benefit processing for individuals from 19 high-risk countries and requiring a re-review of certain previously approved cases. This change may affect work authorization, employment verification, and workforce stability. Employers and HR teams should review impacted employees and update compliance procedures.

CMS Releases CY 2026 Medicare Physician Fee Schedule Final Rule with Key Payment and Telehealth Updates

CMS issued the CY 2026 Medicare Physician Fee Schedule Final Rule on October 31, 2025, with changes effective January 1, 2026. The Final Rule includes increases to the conversion factor, a new efficiency adjustment, updates to practice expense methodology, permanent telehealth policy changes, revised payment for skin substitutes, expanded rules for Part B drugs and biologicals, enhanced policies for Rural Health Clinics and Federally Qualified Health Centers, and new care management and behavioral health services.

Ohio Department of Medicaid Updates: Key Changes to Physician Reimbursement Rates in Early Parenthood

The Ohio Department of Medicaid has proposed amending Ohio Administrative Code Rule related to covered Medicaid reimbursements for physicians. Beginning on January 1, 2026, they are proposing an increase to rates for prenatal care, childbirth, and infant care and provider visits.

Name, Image, and Likeness Agreements in Healthcare

For example, some healthcare providers have begun to utilize "Name, Image, and Likeness" agreements to promote the brand they have created through their healthcare practice.  We have seen the most healthcare NIL activity with longevity and wellness providers, as well as orthopedics.

Compounding GLP-1 Drugs - Recent Updates

Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.